Ultragenyx Pharmaceutical Inc. buy The Goldman Sachs Group, Inc.
Start price
06.06.24
/
50%
€40.80
Target price
06.06.25
€61.55
Performance (%)
-21.08%
End price
07.06.25
€32.20
Summary
This prediction ended on 07.06.25 with a price of €32.20. The price of Ultragenyx Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.08%. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -3.313% | -3.313% | -34.519% |
| iShares Core DAX® | 0.411% | 8.821% | 12.264% |
| iShares Nasdaq 100 | 3.678% | 10.820% | 44.017% |
| iShares Nikkei 225® | 2.701% | 15.247% | 48.041% |
| iShares S&P 500 | 2.445% | 7.933% | 32.998% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $67.00 price target on the stock, up previously from $56.00.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Stopped prediction by The_Goldman_Sachs_Gr for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€46.20
02.08.24
02.08.24
€69.62
02.08.25
02.08.25
-46.75%
03.08.25
03.08.25
